European Medicines Agency recommends extension of indications for paclitaxel protein-bound particles for injectable suspension (albumin-bound)

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Abraxane. The CHMP adopted a new indication as follows: "Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas". Read more here.